
Juul Ban Prompts Praise from Physician Organizations
The FDA ban yesterday on Juul vaping devices and nicotine e-liquid pods drew praise from the American Medical Association, American Thoracic Society, American Lung Association, among others.
This detailed report, including responses from JUUL Labs, the American Lung Association, and the American Thoracic Society, was originally published on our partner site Medical Economics.
The U.S. Food and Drug Administration (FDA) is banning JUUL
On June 23, FDA
The products include the JUUL device and four types of JUULpods: Virginia tobacco flavored pods at nicotine concentrations of 5% and 3% and menthol flavored pods at nicotine concentrations of 5% and 3%.
Retailers should contact JUUL with any questions about products in their inventory. The FDA orders pertain to commercial distribution, importation, and retail sales and do not restrict individual consumer possession and use.
“Today’s action is further progress on the FDA’s commitment to ensuring that all e-cigarette and electronic nicotine delivery system products currently being marketed to consumers meet our public health standards,” FDA Commissioner Robert M. Califf, MD, said in the administration announcement. “The agency has dedicated significant resources to review products from the companies that account for most of the U.S. market. We recognize these make up a significant part of the available products and many have played a disproportionate role in the rise in youth vaping.”
JUUL responds
“We respectfully disagree with the FDA’s findings and decision and continue to believe we have provided sufficient information and data based on high-quality research to address all issues raised by the agency,” said a
“In our applications, which we submitted over two years ago, we believe that we appropriately characterized the toxicological profile of JUUL products, including comparisons to combustible cigarettes and other vapor products, and believe this data, along with the totality of the evidence, meets the statutory standard of being “appropriate for the protection of the public health,” Murillo said. “We intend to seek a stay and are exploring all of our options under the FDA’s regulations and the law, including appealing the decision and engaging with our regulator. We remain committed to doing all in our power to continue serving the millions of American adult smokers who have successfully used our products to transition away from combustible cigarettes, which remain available on market shelves nationwide.”
Physicians react
The FDA ruling sparked praise from at least three medical groups.
The American Lung Association called it “welcomed and long overdue,” in a
The FDA “made the right decision to end the sale of all Juul products including #menthol. They remain one of the most popular e-cigarettes among teens. Stopping these sales is an important step in ending the youth vaping epidemic,” the statement said.
The
“Juul is one of the most popular
American Medical Association President Jack Resneck Jr. issued a
“AMA policy supports banning the sale and distribution of all e-cigarette and vaping products, with the exception of those approved by the FDA for tobacco cessation purposes,” Resneck said. “Since declaring e-cigarette use and vaping an urgent public health epidemic in 2018, the AMA has pushed for more stringent policies to protect young people from the harmful effects of tobacco and nicotine use and will continue do so.”
On Twitter, some people questioned public health priorities in the United States, noting JUUL devices are banned, but cigarettes and other tobacco products remain legal for sale.
Others noted the FDA ruling on vaping was published the same day the
JUUL under review
ATS described the FDA ruling as “based largely on a technical dispute over safety data, rather than JUUL’s appeal among kids,” and not based on “highly addictive levels of nicotine salts,” or long-term health effects.
FDA reviewed JUUL’s request to market the devices, documents known as premarket tobacco product applications, and found they lacked sufficient evidence to show they would be appropriate for the protection of public health.
Some of the company’s study findings raised concerns due to insufficient and conflicting data about effects including genotoxicity, or harm to genetic information within cells, and whether potentially harmful chemicals could leach form the company’s proprietary e-liquid pods, the FDA announcement said.
The FDA acknowledged the administration has not received clinical information to suggest an immediate hazard from the JUUL device or its pods. There is no way to know the potential harms from using third-party e-liquid pods with the JUUL device, or using JUULpods with a non-JUUL device.
“The FDA is tasked with ensuring that tobacco products sold in this country meet the standard set by the law, but the responsibility to demonstrate that a product meets those standards ultimately falls on the shoulders of the company,” said Michele Mital, acting director of the FDA’s Center for Tobacco Products. “As with all manufacturers, JUUL had the opportunity to provide evidence demonstrating that the marketing of their products meets these standards. However, the company did not provide that evidence and instead left us with significant questions. Without the data needed to determine relevant health risks, the FDA is issuing these marketing denial orders.”
Quitting smoking
The FDA announcement linked to its
“Quitting all tobacco products is the best possible path to good health,” it said, but the FDA also has approved other ENDS products with potential to benefit adult smokers.
The ruling about JUUL products marks the third significant FDA action on cigarettes, tobacco or electronic nicotine delivery systems in the last two months.
On June 21, the White House published plans for future regulatory actions with FDA plans to establish a maximum nicotine level to reduce the addictiveness of cigarettes.
In April, FDA proposed
That FDA action deals with manufacturers, distributors, wholesalers, importers and retailers who make, distribute or sell the products. FDA “cannot and will not enforce against individual consumers for possession or use of menthol cigarettes or flavored cigars,” the agency announcement said.
FDA is in a public comment period until July 5 for that ban.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.